Phibro Animal Health (NASDAQ:PAHC) Reaches New 52-Week High After Analyst Upgrade

Shares of Phibro Animal Health Corporation (NASDAQ:PAHC) hit a new 52-week high on Monday after JPMorgan Chase & Co. raised their price target on the stock from $45.00 to $50.00. JPMorgan Chase & Co. currently has an overweight rating on the stock. Phibro Animal Health traded as high as $45.13 and last traded at $45.0950, with a volume of 58480 shares traded. The stock had previously closed at $43.76.

Several other analysts have also weighed in on the stock. Bank of America lifted their price objective on shares of Phibro Animal Health from $19.00 to $27.00 and gave the company an “underperform” rating in a research note on Friday, August 29th. Zacks Research upgraded Phibro Animal Health from a “hold” rating to a “strong-buy” rating in a research note on Monday, September 29th. Weiss Ratings upgraded shares of Phibro Animal Health from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Wednesday. Finally, Morgan Stanley set a $34.00 target price on shares of Phibro Animal Health in a report on Thursday, August 28th. One investment analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, three have assigned a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $31.40.

Insider Transactions at Phibro Animal Health

In related news, CEO Jack Bendheim sold 3,520 shares of Phibro Animal Health stock in a transaction dated Tuesday, November 4th. The stock was sold at an average price of $43.10, for a total value of $151,712.00. Following the completion of the sale, the chief executive officer owned 65,920 shares of the company’s stock, valued at approximately $2,841,152. This trade represents a 5.07% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Insiders sold 67,336 shares of company stock valued at $2,734,588 over the last three months. Company insiders own 50.13% of the company’s stock.

Institutional Trading of Phibro Animal Health

A number of institutional investors have recently modified their holdings of the business. National Bank of Canada FI bought a new stake in Phibro Animal Health during the 1st quarter valued at $30,000. Financial Management Professionals Inc. bought a new stake in shares of Phibro Animal Health during the 2nd quarter valued at $32,000. EverSource Wealth Advisors LLC lifted its holdings in Phibro Animal Health by 7,671.4% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 2,720 shares of the company’s stock worth $69,000 after purchasing an additional 2,685 shares in the last quarter. Tower Research Capital LLC TRC boosted its stake in Phibro Animal Health by 768.2% in the 2nd quarter. Tower Research Capital LLC TRC now owns 4,610 shares of the company’s stock worth $118,000 after purchasing an additional 4,079 shares during the period. Finally, Quantbot Technologies LP boosted its stake in Phibro Animal Health by 53.8% in the 1st quarter. Quantbot Technologies LP now owns 7,870 shares of the company’s stock worth $168,000 after purchasing an additional 2,754 shares during the period. 99.34% of the stock is currently owned by hedge funds and other institutional investors.

Phibro Animal Health Stock Up 3.2%

The stock has a fifty day simple moving average of $39.71 and a two-hundred day simple moving average of $31.04. The firm has a market cap of $1.83 billion, a PE ratio of 38.28, a price-to-earnings-growth ratio of 1.24 and a beta of 0.81. The company has a current ratio of 2.76, a quick ratio of 1.25 and a debt-to-equity ratio of 2.46.

Phibro Animal Health (NASDAQ:PAHC) last released its quarterly earnings data on Wednesday, November 5th. The company reported $0.73 EPS for the quarter, beating analysts’ consensus estimates of $0.58 by $0.15. The company had revenue of $363.89 million during the quarter, compared to analyst estimates of $345.44 million. Phibro Animal Health had a net margin of 3.73% and a return on equity of 32.14%. Phibro Animal Health has set its FY 2026 guidance at 2.640-2.810 EPS. As a group, sell-side analysts expect that Phibro Animal Health Corporation will post 1.95 EPS for the current fiscal year.

Phibro Animal Health Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Wednesday, December 17th. Stockholders of record on Wednesday, November 26th will be issued a $0.12 dividend. The ex-dividend date of this dividend is Wednesday, November 26th. This represents a $0.48 dividend on an annualized basis and a dividend yield of 1.1%. Phibro Animal Health’s dividend payout ratio is presently 28.92%.

Phibro Animal Health Company Profile

Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Israel, Brazil, Ireland, and internationally. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets various products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture, and dogs.